T. Tuğlular

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

B. Ferhanoğlu, L. Kaynar, M. Yenerel, 2022, Annals of Hematology.

P1227: POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY

B. Ferhanoğlu, L. Kaynar, M. Yenerel, 2022, Annals of hematology.

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

B. Ferhanoğlu, L. Kaynar, M. Yenerel, 2022, Annals of Hematology.